Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 212


Home  | About Us | Editors | Search | Ahead Of Print | Current Issue | Archives | Submit Article | Instructions | Subscribe | Contacts | Login 
Year : 2022  |  Volume : 12  |  Issue : 2  |  Page : 95-100

Hematological manifestations of COVID-19 acute respiratory distress syndrome patients and the impact of thrombocytopenia on disease outcomes: A retrospective study

1 COVID Intensive Care Unit, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Internal Diseases and Intensive Care, Ankara, Turkey
2 Department of Chest Diseases, COVID Intensive Care Unit, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
3 Intern Doctor, School of Medicine, Bahcesehir University, Istanbul, Turkey
4 Department of General Surgery, COVID Intensive Care Unit, University of Health Sciences, Dişkapi Yildirim Beyazit Research and Education Hospital, Ankara, Turkey

Correspondence Address:
Dr. Fatma Yildirim
Department of Chest Diseases, COVID Intensive Care Unit, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijciis.ijciis_96_21

Rights and Permissions

Background: Platelet count is a simple and readily available biomarker, in which thrombocytopenia was shown to be independently associated with disease severity and risk of mortality in the critical coronavirus disease-19 (COVID-19) patients. The aim of this study was to investigate the impact of thrombocytopenia on disease progression in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS) admitted to a medical intensive care unit (ICU). Methods: COVID-19-associated ARDS patients in our research hospitals' ICU were retrospectively investigated. Patients were divided into two groups as thrombocytopenic (<150 × 109/ml) patients on admission or those who developed thrombocytopenia during ICU follow-up (Group 1) and those without thrombocytopenia during ICU course and follow-up (Group 2). Results: The median platelet count of all patients was 240 × 109/ml, and the median D-dimer was 1.16 mg/ml. On admission, 32 (18.3%) patients had thrombocytopenia. The mean platelet count of Group 1 was 100.0 ± 47.5 × 109/ml. Group 1 was older and their Acute Physiology and Chronic Health Evaluation II and sequential organ failure assessment scores were higher. Group 1 had lower hemoglobin, neutrophil, and lymphocyte counts and higher ferritin and procalcitonin level. Invasive mechanical ventilation was more commonly needed, and disseminated intravascular coagulation (DIC) was more frequently observed in Group 1. The ICU and hospital length of stay of Group 1 was longer with higher mortality. Conclusion: Patients with thrombocytopenia had increased inflammatory markers, frequency of DIC, duration of ICU stay, and mortality. The presence of thrombocytopenia may reflect the progression of COVID-19 toward an unfavorable outcome.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal